Security
Ascendis Pharma A/S Ordinary Share · ASND
ASNDNASDAQCommon stockCurrentCIK 1612042Updated Oct 27, 2026
ASND price & chart
Loading TradingView…
NASDAQ:ASND on TradingView ↗About the company
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
In the news
Ascendis Announces Planned $400 Million Share Repurchase Program ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
Source
Source
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossEUR | — | — | -60,989,000Source | -99,198,000Source | -38,855,000Source | -109,380,000Source | -94,626,000Source | -131,035,000Source | -228,034,000Source | -378,084,000Source | -481,447,000Source | -583,194,000Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | — | — | — | — | — | — | — | — | 513,000Source | -126,000Source | 3,904,000Source | — |
| AdjustmentsForDeferredTaxOfPriorPeriodsEUR | — | — | — | — | — | — | — | — | 70,000Source | 607,000Source | -4,786,000Source | — |
| AdjustmentsForSharebasedPaymentsEUR | — | — | — | — | — | — | 25,558,000Source | 17,281,000Source | 116,171,000Source | 95,512,000Source | 66,660,000Source | 64,180,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | 52,000Source | 206,000Source | 6,679,000Source | 5,512,000Source | 4,466,000Source | 3,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | — | — | — | — | 10,438,000Source | 6,356,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesEUR | — | — | — | — | — | — | 17,396,000Source | — | 17,396,000Source | 0Source | 0Source | 105,305,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | — | — | 0Source | 134,158,000Source | 136,256,000Source | — |
| ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssetsEUR | — | — | — | — | — | — | — | 7,354,000Source | — | — | 288,865,000Source | 280,528,000Source |
| ProceedsFromIssuingSharesEUR | — | — | — | — | — | — | — | — | 0Source | 309,913,000Source | 0Source | — |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | — | — | — | — | — | — | — | — | 0Source | 950,000Source | 51,000Source | — |
| PurchaseOfInterestsInAssociatesEUR | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | 3,066,000Source | 2,786,000Source | 21,958,000Source | 11,365,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseEUR | — | — | 113,404,000Source | 69,831,000Source | 107,561,000Source | 74,312,000Source | 101,046,000Source | 66,783,000Source | 457,867,000Source | 291,142,000Source | 264,410,000Source | 221,227,000Source |
| Total RevenueEUR | — | — | 213,634,000Source | 57,833,000Source | 158,045,000Source | 35,998,000Source | 100,954,000Source | 95,894,000Source | 720,132,000Source | 363,641,000Source | 266,718,000Source | 51,174,000Source |
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.22Source | 0.22Source | 0.22Source | 0.22Source |
| AuditorsRemunerationForTaxServicesEUR | — | — | — | — | — | — | — | — | 0Source | 91,000Source | 122,000Source | 138,000Source |
| AverageEffectiveTaxRatenumber | — | — | — | — | — | — | — | — | 0.07Source | 0.01Source | 0.02Source | -0.01Source |
| BasicEarningsLossPerShareEUR/shares | — | — | -1Source | -1.72Source | -0.64Source | -1.91Source | -1.58Source | -2.3Source | -3.76Source | -6.53Source | -8.55Source | — |
| CurrentTaxExpenseIncomeEUR | — | — | — | — | — | — | — | — | -12,556,000Source | -3,289,000Source | -5,377,000Source | -5,377,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR | — | — | — | — | — | — | — | — | -3,340,000Source | — | — | — |
| DepreciationRightofuseAssetsEUR | — | — | — | — | — | — | — | — | 12,350,000Source | 12,312,000Source | 11,875,000Source | 11,740,000Source |
| DilutedEarningsLossPerShareEUR/shares | — | — | — | -1.72Source | — | -1.91Source | -1.58Source | -2.3Source | -3.76Source | -6.53Source | -8.55Source | — |
| EmployeeBenefitsExpenseEUR | — | — | — | — | — | — | — | — | 376,565,000Source | 292,535,000Source | 258,456,000Source | 214,661,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | — | — | — | — | — | — | — | — | 116,171,000Source | 95,512,000Source | 66,660,000Source | 64,180,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR | — | — | — | — | — | — | — | — | — | 285,000Source | 353,000Source | 280,000Source |
| FinanceCostsEUR | — | — | 66,904,000Source | 25,347,000Source | 33,018,000Source | 19,624,000Source | 44,786,000Source | 77,161,000Source | 206,687,000Source | 100,027,000Source | 44,065,000Source | 50,487,000Source |
| FinanceIncomeEUR | — | — | 6,036,000Source | 28,279,000Source | 55,059,000Source | 49,052,000Source | 28,854,000Source | 3,575,000Source | 113,999,000Source | 25,609,000Source | 43,857,000Source | 52,181,000Source |
| GrossProfitEUR | — | — | 191,280,000Source | 46,632,000Source | 126,598,000Source | 24,533,000Source | 83,437,000Source | 88,325,000Source | 625,217,000Source | 319,383,000Source | 222,323,000Source | 39,037,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | — | — | 3,617,000Source | 1,020,000Source | 3,848,000Source | 229,000Source | 1,061,000Source | 2,508,000Source | 15,383,000Source | 4,843,000Source | 7,303,000Source | 5,377,000Source |
| InterestExpenseEUR | — | — | — | — | — | — | — | — | 80,647,000Source | 65,504,000Source | 44,065,000Source | 30,682,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | — | — | — | — | — | — | — | — | 4,186,000Source | 3,303,000Source | 3,581,000Source | 3,842,000Source |
| NetForeignExchangeLossEUR | — | — | — | — | — | — | — | — | 0Source | 27,149,000Source | — | — |
| OtherEmployeeExpenseEUR | — | — | — | — | — | — | — | — | 5,221,000Source | 4,061,000Source | 4,238,000Source | — |
| OtherFinanceCostEUR | — | — | — | — | — | — | — | — | — | — | — | 4,322,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansEUR | — | — | — | — | — | — | — | — | 6,921,000Source | 4,485,000Source | 4,403,000Source | 4,163,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | — | — | -60,989,000Source | -99,198,000Source | -38,855,000Source | -109,380,000Source | -94,626,000Source | -131,035,000Source | -228,034,000Source | -378,084,000Source | -481,447,000Source | -583,194,000Source |
| ProfitLossBeforeTaxEUR | — | — | -57,372,000Source | -98,178,000Source | -35,007,000Source | -109,151,000Source | -93,565,000Source | -128,527,000Source | -212,651,000Source | -373,241,000Source | -474,144,000Source | -577,817,000Source |
| ProfitLossFromOperatingActivitiesEUR | — | — | 10,997,000Source | -96,743,000Source | -52,951,000Source | -133,257,000Source | -104,212,000Source | -49,145,000Source | -136,271,000Source | -278,763,000Source | -455,541,000Source | -561,814,000Source |
| ResearchAndDevelopmentExpenseEUR | — | — | 66,879,000Source | 73,544,000Source | 71,988,000Source | 83,478,000Source | 86,603,000Source | 70,687,000Source | 303,621,000Source | 307,004,000Source | 413,454,000Source | 379,624,000Source |
| RevenueFromInterestEUR | — | — | — | — | — | — | — | — | 15,301,000Source | 14,361,000Source | 16,857,000Source | 7,426,000Source |
Filing attachments
d31437dex991.htm · 6-K · 2026-08-13
Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Second Quarter 2026 Financial Results Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH®, €55 million for SKYTROFA®, and €8 million for YUVIWEL® ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Through July 31, more than 220 unique YUVIWEL patient enrollments in the U.S. ───────────────────────…
Read attachment ↗d121855dex991.htm · 6-K · 2026-05-07
Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports First Quarter 2026 Financial Results - Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, …
Read attachment ↗d89195dex991.htm · S-8 · 2026-02-27
Exhibit 99.1 Ascendis Pharma A/S ──────────────────────────── Restricted Stock Unit Program ────────────────────────────────────── Terms and Conditions, 1 March 2026 1 Introduction and purpose ──────────────────────────────────── 1.1 The purpose of this document is to set out the general terms and conditions for the Restricted Stock Unit Program (the “RSU Program”) of Ascendis Pharma A/S, CVR no. 29918791 (the “Company”). These general terms and co…
Read attachment ↗d89195dex992.htm · S-8 · 2026-02-27
Exhibit 99.2 Ascendis Pharma A/S Performance Stock Unit Program Terms and Conditions, 1 March 2026 1 Introduction and purpose ──────────────────────────────────── 1.1 The purpose of this document is to set out the general terms and conditions for the Performance Stock Unit Program (the “PSU Program”) of Ascendis Pharma A/S, CVR no. 29918791 (the “Company”). These general terms and conditions (the “Terms and Conditions”) apply to all performance stock units granted…
Read attachment ↗d112586dex991.htm · 6-K · 2026-02-23
Exhibit 99.1 Notice to Convene Annual General Meeting 2026 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the “Company”) will be held on: March 23, 2026 at 2:00 p.m. CET The annual general meeting will be held at: Mazanti-Andersen, Amaliegade 10, DK-1256 Copenhagen K, Denmark The agenda for the annual general meeting is as follows: Election of Chair of the Meeting ──────────────────────────────────── Report on the Company’s Activities during the Past …
Read attachment ↗d112586dex992.htm · 6-K · 2026-02-23
Exhibit 99.2 Ascendis Pharma A/S Tuborg Boulevard 12 DK-2900 Hellerup Central Business Registration No. 29 91 87 91 Annual Report 2025 (January 1 - December 31) Adopted at the Annual General Meeting of Shareholders on March 23, 2026. Lars Lüthjohan Jensen Chairman of the General Meeting Contents Company Information 3 Statement by Management on the Annual Report …
Read attachment ↗